Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRC

In Partnership With:

Partner | Cancer Centers | <b>Sarah Cannon Research Institute</b>

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).